logo

For the Inventor, By the Inventor

Mainz, Germany

Biontech Ag


USPTO Granted Patents = 37

% Expired Patents = 13.5



Forward Citations = 173

Loading Chart...
Loading Chart...

68 inventors (with patents filed for the assignee):

goldMedal Ugur Sahin (27 out of 196 patents)

silverMedal Özlem Türeci (11 out of 53 patents)

bronzeMedal Ozlem Tureci (11 out of 54 patents)

4.  Michael Koslowski (9 out of 53 patents)

5.  Gerd Helftenbein (6 out of 15 patents)

6.  Volker Schlüter (6 out of 13 patents)

7.  Sebastian Kreiter (5 out of 27 patents)

8.  Steve Pascolo (4 out of 24 patents)

9.  Jens Schumacher (4 out of 5 patents)

10.  Markus Fiedler (3 out of 13 patents)

11.  Dirk Usener (3 out of 19 patents)

12.  Stefano Maiorana (2 out of 28 patents)

13.  Thomas Michael Hiller (2 out of 6 patents)

14.  Holger Hoff (2 out of 5 patents)

15.  Dieter Moosmayer (2 out of 8 patents)


Core Competencies:
Individualized Vaccines
Cancer Stem Cells
Cytotoxic Particles
RNA Formulations
Tumor Antigens
Antibody-Mediated Activation
Immunomodulation
Tumor Vaccination
Genetic Products
Humoral Immune Response
Claudin Expressing Diseases
Proapoptotic Cytokines

37 patents:

1. 12642844 - INDIVIDUALIZED VACCINES FOR CANCER (2026-06-02),
2. 11795218 - Diagnosis and therapy of cancer involving cancer stem cells (2023-10-24),
3. 10980875 - Cytotoxic immunostimulating particles and uses thereof (2021-04-20),
4. 10717780 - Agents for treatment of claudin expressing cancer diseases (2020-07-21),
5. 10626400 - Stabilised formulations of RNA (2020-04-21),
6. 10604568 - Diagnosis and therapy of cancer involving cancer stem cells (2020-03-31),
7. 10370433 - Compositions and methods for diagnosis and treatment of cancer (2019-08-06),
8. 10302647 - Identification of surface-associated antigens for tumor diagnosis and therapy (2019-05-28),
9. 10253373 - Identification of tumor-associated markers for diagnosis and therapy (2019-04-09),
10. 10188712 - Tumor antigens for determining cancer therapy (2019-01-29),
11. 10172960 - Particles comprising single stranded RNA and double stranded RNA for immunomodulation (2019-01-08),
12. 10106800 - Modification of RNA, producing an increased transcript stability and translation efficiency (2018-10-23),
13. 10093736 - Agents for treatment of claudin expressing cancer diseases (2018-10-09),
14. 9944708 - Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines) (2018-04-17),
15. 9910043 - Identification of tumor-associated cell surface antigens for diagnosis and therapy (2018-03-06),
Company Overview
BioNTech SE, headquartered in Mainz, Germany, is a biotechnology company focused on developing and manufacturing innovative therapies for cancer and other serious diseases. The company specializes in mRNA technology, which has gained prominence for its role in vaccine development, particularly in the context of infectious diseases. BioNTech's research encompasses various domains, including immunotherapy and personalized medicine, aiming to harness the body's immune system to fight diseases more effectively.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

37 Patents

#10 in Mainz

#1,370 in Germany

#18,281 in the World

Mainz, DE
Mainz, Germany

Biontech Ag

Forward Citations = 173

68 inventors:

goldMedal Ugur Sahin (27 out of 196 patents)

silverMedal Özlem Türeci (11 out of 53 patents)

bronzeMedal Ozlem Tureci (11 out of 54 patents)

4.  Michael Koslowski (9 out of 53 patents)

5.  Gerd Helftenbein (6 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biontech Ag. Retrieved from https://idiyas.com/company/biontech-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…